APP and Alzheimer disease: In a study in which AD was induced in rats by Aβ25–35A injection, it was found that HLJDD significantly improved learning and memory impairment, decreased Aβ25–35 and APP levels in the hippocampus, increased SOD and GSH activities, reduced MDA concentrations and alleviated nuclear and cytoplasmic abnormalities in the hippocampal CA1 region (Wu et al., 2020).